Advances in molecular imaging: Targeted optical contrast agents for cancer diagnostics

Nanomedicine

Volumn 7, Issue 3, 2012, Pages 429-445

  Hellebust, Anne ^a   Richards Kortum, Rebecca ^a  

^a RICE UNIVERSITY   (United States)

Author keywords

biomarkers; cancer; contrast agents; early diagnosis; image guided therapeutics; nanoparticles; optical imaging

Indexed keywords

BIOLOGICAL MARKER; CONTRAST MEDIUM; NANOCRYSTAL; NANOPARTICLE; NANOSHELL;

CANCER DIAGNOSIS; CANCER GROWTH; CANCER STAGING; CLINICAL EFFECTIVENESS; EARLY DIAGNOSIS; EX VIVO STUDY; FLUORESCENCE IMAGING; MICROSCOPY; MOLECULAR DIAGNOSIS; MOLECULAR IMAGING; MORTALITY; PRIORITY JOURNAL; REVIEW; SEMICONDUCTOR;

ANIMALS; CONTRAST MEDIA; FLUORESCENT DYES; HUMANS; MOLECULAR IMAGING; NANOPARTICLES; NEOPLASMS;

EID: 84857870240     PISSN: 17435889     EISSN: 17486963     Source Type: Journal    
DOI: 10.2217/nnm.12.12     Document Type: Review

References (116)

1. Vieth M, Ell C, Gossner L, May A, Stolte M. Histological analysis of endoscopic resection specimens from 326 patients with Barrett's esophagus and early neoplasia. Endoscopy 36(9), 776-781 (2004).
2. Yao SL, Lu-Yao GL. The science and art of prostate cancer screening. J. Natl Cancer Inst. 103(6), 450-450 (2011).
3. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 100(1), 57-70 (2000).
4. Glunde K, Pathak A, Bhujwalla Z. Molecular-functional imaging of cancer: to image and imagine. Trends Mol. Med. 13(7), 287-297 (2007).
5. Hong WK, Sporn MB. Recent advances in chemoprevention of cancer. Science 278(5340), 1073-1077 (1997).
6. Pomper MG. Molecular imaging: An overview. Acad. Radiol. 8(11), 1141-1153 (2001).
7. Moore SG, Shenoy PJ, Fanucchi L, Tumeh JW, Flowers CR. Cost-effectiveness of MRI compared with mammography for breast cancer screening in a high-risk population. BMC Health Serv. Res. 9, 9 (2009).
8. Louie AY. Multimodality imaging probes: design and challenges. Chem. Rev. 110(5), 3146-3195 (2010). nn Overview of advances in multimodal imaging with a specific focus on the combination of optical imaging and MRI.
9. Pierce MC, Javier DJ, Richards-Kortum R. Optical contrast agents and imaging systems for detection and diagnosis of cancer. Int. J. Cancer 123(9), 1979-1990 (2008).
10. Rajadhyaksha M, Grossman M, Esterowitz D, Webb RH, Anderson RR. In vivo confocal scanning laser microscopy of human skin: melanin provides strong contrast. J. Invest. Dermatol. 104(6), 946-952 (1995).
11. Lane PM, Gilhuly T, Whitehead P et al. Simple device for the direct visualization of oral-cavity tissue fluorescence. J. Biomed. Opt. 11(2), 024006 (2006).
12. Frangioni JV. New technologies for human cancer imaging. J. Clin. Oncol. 26(24), 4012-4021 (2008).
13. Weissleder R, Pittet MJ. Imaging in the era of molecular oncology. Nature 452(7187), 580-589 (2008).
14. Curvers WL, Singh R, Song L et al. Endoscopic tri-modal imaging for detection of early neoplasia in Barrett's oesophagus: A multi-centre feasibility study using high-resolution endoscopy, autofluorescence imaging and narrow band imaging incorporated in one endoscopy system. Gut 57(2), 167-172 (2008).
15. Lam S, Macaulay C, Leriche JC, Palcic B. Detection and localization of early lung cancer by fluorescence bronchoscopy. Cancer 89(11), 2468-2473 (2000).
16. Park SY, Follen M, Milbourne A et al. Automated image analysis of digital colposcopy for the detection of cervical neoplasia. J. Biomed. Opt. 13(1), 4029 (2008).
17. Roblyer D, Richards-Kortum R, Sokolov K et al. Multispectral optical imaging device for in vivo detection of oral neoplasia. J. Biomed. Opt. 13(2), 024019 (2008).
18. Poh CF, Ng SP, Williams PM et al. Direct fluorescence visualization of clinically occult high-risk oral premalignant disease using a simple hand-held device. Head Neck 29(1), 71-76 (2007).
19. East JE, Suzuki N, Saunders BP. Comparison of magnified pit pattern interpretation with narrow band imaging versus chromoendoscopy for diminutive colonic polyps: A pilot study. Gastrointest. Endosc. 66(2), 310-316 (2007).
20. Suzuki H, Saito Y. Autofluorescence and narrow-band imaging endoscopy for detecting early-staged cancer in Barrett's esophagus: A case report. Jpn J. Clin. Oncol. 38(12), 871-871 (2008).
21. Van Den Broek FJC, Fockens P, Van Eeden S et al. Endoscopic tri-modal imaging for surveillance in ulcerative colitis: Randomised comparison of high-resolution endoscopy and autofluorescence imaging for neoplasia detection; and evaluation of narrow-band imaging for classification of lesions. Gut 57(8), 1083-1089 (2008).
22. Luo S, Zhang E, Su Y, Cheng T, Shi C. A review of NIR dyes in cancer targeting and imaging. Biomaterials 32(29), 7127-7138 (2011).
23. Mather S. Molecular imaging with bioconjugates in mouse models of cancer. Bioconj. Chem. 20(4), 631-643 (2009).
24. Doubrovin M, Serganova I, Mayer-Kuckuk P, Ponomarev V, Blasberg RG. Multimodality in vivo molecular-genetic imaging. Bioconj. Chem. 15(6), 1376-1388 (2004).
25. Hilger I, Leistner Y, Berndt A et al. Near-infrared fluorescence imaging of HER-2 protein over-expression in tumour cells. Eur. Radiol. 14(6), 1124-1129 (2004).
26. Hsu ER, Anslyn EV, Dharmawardhane S et al. A far-red fluorescent contrast agent to image epidermal growth factor receptor expression. Photochem. Photobiol. 79(3), 272-279 (2004).
27. Chang SK, Rizvi I, Solban N, Hasan T. In vivo optical molecular imaging of vascular endothelial growth factor for monitoring cancer treatment. Clin. Cancer Res. 14(13), 4146-4153 (2008).
28. Hoetker MS, Foersch S, Galle PR, Ralf K, Goetz M. Molecular in vivo imaging of gastrointestinal neoplasia with endomicroscopy using therapeutic antibodies against EGFR. Digestive Disease Week. Chicago, IL, USA, 7-10 May 2011.
29. Foersch S, Kiesslich R, Hoetker MS, Galle PR, Neurath MF, Goetz M. In vivo immunohistochemistry with labeled bevacizumab using confocal laser endomicroscopy in models of human colorectal cancer. Digestive Disease Week. Chicago, IL, USA, 7-10 May 2011.
30. Holliger P, Hudson PJ. Engineered antibody fragments and the rise of single domains. Nat. Biotechnol. 23(9), 1126-1136 (2005).
31. Lee S, Xie J, Chen X. Peptide-based probes for targeted molecular imaging. Biochemistry 49(7), 1364-1376 (2010).
32. Reubi JC, Maecke HR. Peptide-based probes for cancer imaging. J. Nucl. Med. 49(11), 1735-1738 (2008).
33. Nitin N, Rosbach KJ, El-Naggar A, Williams M, Gillenwater A, Richards-Kortum RR. Optical molecular imaging of epidermal growth factor receptor expression to improve detection of oral neoplasia. Neoplasia 11(6), 542-551 (2009).
34. Ke S, Wen XX, Gurfinkel M et al. Near-infrared optical imaging of epidermal growth factor receptor in breast cancer xenografts. Cancer Res. 63(22), 7870-7875 (2003).
35. Adams KE, Ke S, Kwon S et al. Comparison of visible and near-infrared wavelength-excitable fluorescent dyes for molecular imaging of cancer. J. Biomed. Opt. 12(2), 024017 (2007).
36. Hsiung PL, Hardy J, Friedland S et al. Detection of colonic dysplasia in vivo using a targeted heptapeptide and confocal microendoscopy. Nature Med. 14(4), 454-458 (2008).
37. Kelly K, Alencar H, Funovics M, Mahmood U, Weissleder R. Detection of invasive colon cancer using a novel, targeted, library-derived fluorescent peptide. Cancer Res. 64(17), 6247-6251 (2004).
38. Li M, Anastassiades CP, Joshi B et al. Affinity peptide for targeted detection of dysplasia in Barrett's esophagus. Gastroenterology 139(5), 1472-1480 (2010).
39. Kelly KA, Waterman P, Weissleder R. In vivo imaging of molecularly targeted phage. Neoplasia 8(12), 1011-1018 (2006).
40. Newton JR, Kelly KA, Mahmood U, Weissleder R, Deutscher SL. In vivo selection of phage for the optical imaging of PC-3 human prostate carcinoma in mice. Neoplasia 8(9), 772-780 (2006).
41. Cheng Z, Wu Y, Xiong ZM, Gambhir SS, Chen XY. Near-infrared fluorescent RGD peptides for optical imaging of integrin alpha(v)beta 3 expression in living mice. Bioconj. Chem. 16(6), 1433-1441 (2005).
42. Kelly KA, Setlur SR, Ross R et al. Detection of early prostate cancer using a hepsin-targeted imaging agent. Cancer Res. 68(7), 2286-2291 (2008).
43. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 144(5), 646-674 (2011).
44. Levi J, Cheng Z, Gheysens O et al. Fluorescent fructose derivatives for imaging breast cancer cells. Bioconj. Chem. 18(3), 628-634 (2007).
45. Cheng Z, Levi J, Xiong ZM et al. Near-infrared fluorescent deoxyglucose analogue for tumor optical imaging in cell culture and living mice. Bioconj. Chem. 17(3), 662-669 (2006).
46. Nitin N, Carlson AL, Muldoon T, El-Naggar AK, Gillenwater A, Richards-Kortum R. Molecular imaging of glucose uptake in oral neoplasia following topical application of fluorescently labeled deoxy-glucose. Int. J. Cancer 124(11), 2634-2642 (2009).
47. Langsner R, Middleton L, Sun J et al. Wide-field imaging of fluorescent deoxy-glucose in ex vivo malignant and normal breast tissue. Biomed. Opt. Express 2(6), 1514-1523 (2011).
48. Sheth RA, Josephson L, Mahmood U. Evaluation and clinically relevant applications of a fluorescent imaging analog to fluorodeoxyglucose positron emission tomography. J. Biomed. Opt. 14(6), 064014 (2009). n Details the use of a fluorescently labeled glucose analog for minimally invasive detection of neoplasia and intraoperative imaging.
49. Messerli SM, Prabhakar S, Tang Y et al. A novel method for imaging apoptosis using a caspase-1 near-infrared fluorescent probe. Neoplasia 6(2), 95-105 (2004).
50. Sheth RA, Upadhyay R, Stangenberg L, Sheth R, Weissleder R, Mahmood U. Improved detection of ovarian cancer metastases by intraoperative quantitative fluorescence protease imaging in a pre-clinical model. Gynecol. Oncol. 112(3), 616-622 (2009).
51. Gounaris E, Tung CH, Restaino C et al. Live imaging of cysteine-cathepsin activity reveals dynamics of focal inflammation, angiogenesis, and polyp growth. PLoS One 3(8), e2916 (2008).
52. Kobayashi H, Choyke PL. Target-cancer-cell-specific activatable fluorescence imaging probes: Rational design and in vivo applications. Acc. Chem. Res. 44(2), 83-90 (2011).
53. Jiang T, Olson ES, Nguyen QT, Roy M, Jennings PA, Tsien RY. Tumor imaging by means of proteolytic activation of cell-penetrating peptides. Proc. Natl Acad. Sci. USA 101(51), 17867-17872 (2004).
54. Nguyen QT, Olson ES, Aguilera TA et al. Surgery with molecular fluorescence imaging using activatable cell-penetrating peptides decreases residual cancer and improves survival. Proc. Natl Acad. Sci. USA 107(9), 4317-4322 (2010). n Provides an example of a multimodal imaging agent with cell-penetrating capabilities used to improve preoperative and intraoperative imaging.
55. Bao G, Rhee WJ, Tsourkas A. Fluorescent probes for live-cell RNA detection. Annu. Rev. Biomed. Eng. 11, 25-47 (2009). n Overview of RNA imaging in living cells with fluorescent probes.
56. Rhee WJ, Bao G. Simultaneous detection of mRNA and protein stem cell markers in live cells. BMC Biotechnol. 9, 30 (2009).
57. Nabiev IR, Morjani H, Manfait M. Selective analysis of antitumor drug interaction with living cancer cells as probed by surface-enhanced Raman spectroscopy. Eur. Biophys. J. 19(6), 311-316 (1991).
58. Kneipp K, Haka AS, Kneipp H et al. Surface-enhanced raman spectroscopy in single living cells using gold nanoparticles. Appl. Spectroscopy 56(2), 150-154 (2002).
59. Nie S, Emory SR. Probing single molecules and single nanoparticles by surface-enhanced Raman scattering. Science 275(5303), 1102-1106 (1997).
60. Elghanian R, Storhoff JJ, Mucic RC, Letsinger RL, Mirkin CA. Selective colorimetric detection of polynucleotides based on the distance-dependent optical properties of gold nanoparticles. Science 277(5329), 1078-1080 (1997).
61. Yasuda R, Noji H, Yoshida M, Kinosita K Jr, Itoh H. Resolution of distinct rotational substeps by submillisecond kinetic analysis of F1-ATPase. Nature 410(6831), 898-904 (2001).
62. Schultz S, Smith DR, Mock JJ, Schultz DA. Single-target molecule detection with nonbleaching multicolor optical immunolabels. Proc. Natl Acad. Sci. USA 97(3), 996-1001 (2000).
63. Yguerabide J, Yguerabide EE. Resonance light scattering particles as ultrasensitive labels for detection of analytes in a wide range of applications. J. Cell. Biochem. Suppl. 37, 71-81 (2001).
64. Sonnichsen C, Reinhard Bjorn M, Liphardt J, Alivisatos AP. A molecular ruler based on plasmon coupling of single gold and silver nanoparticles. Nat. Biotechnol. 23(6), 741-745. (2005).
65. Yguerabide J, Yguerabide EE. Light-scattering submicroscopic particles as highly fluorescent analogs and their use as tracer labels in clinical and biological applications. Anal. Biochem. 262(2), 137-156 (1998).
66. Shaner NC, Steinbach PA, Tsien RY. A guide to choosing fluorescent proteins. Nat. Methods 2(12), 905-909 (2005).
67. Patterson GH, Knobel SM, Sharif WD, Kain SR, Piston DW. Use of the green fluorescent protein and its mutants in quantitative fluorescence microscopy. Biophys. J. 73, 2782-2790 (1997).
68. Horisberger M, Rosset J, Bauer H. Colloidal gold granules as markers for cell surface receptors in the scanning electron microscope. Experientia 31(10), 1147-1149 (1975).
69. Sokolov K, Follen M, Aaron J et al. Real-time vital optical imaging of precancer using anti-epidermal growth factor receptor antibodies conjugated to gold nanoparticles. Cancer Res. 63(9), 1999-2004 (2003).
70. Kumar S, Harrison N, Richards-Kortum R, Sokolov K. Plasmonic nanosensors for imaging intracellular biomarkers in live cells. Nano Letters 7(5), 1338-1343 (2007).
71. Chen K, Liu Y, Ameer G, Backman V. Optimal design of structured nanospheres for ultrasharp light-scattering resonances as molecular imaging multilabels. J. Biomed. Opt. 10(2), 024005 (2005).
72. Adler DC, Huang S-W, Huber R, Fujimoto JG. Photothermal detection of gold nanoparticles using phase-sensitive optical coherence tomography. Optics Express 16(7), 4376-4393 (2008).
73. Hirsch LR, Stafford RJ, Bankson JA et al. Nanoshell-mediated near-infrared thermal therapy of tumors under magnetic resonance guidance. Proc. Natl Acad. Sci. USA 100(23), 13549-13554 (2003).
74. Loo C, Lowery A, Halas N, West J, Drezek R. Immunotargeted nanoshells for integrated cancer imaging and therapy. Nano Letters 5(4), 709-711 (2005).
75. Huang X, El-Sayed IH, Qian W, El-Sayed MA. Cancer cell imaging and photothermal therapy in the near-infrared region by using gold nanorods. J. Am. Chem. Soc. 128(6), 2115-2120 (2006).
76. Pissuwan D, Valenzuela SM, Killingsworth MC, Xu X, Cortie MB. Targeted destruction of murine macrophage cells with bioconjugated gold nanorods. J. Nanopart. Res. 9(6), 1109-1124 (2007).
77. Skrabalak SE, Chen J, Au L, Lu X, Li X, Xia Y. Gold nanocages for biomedical applications. Adv. Mater. 19(20), 3177-3184 (2007).
78. Larson T, Travis K, Joshi P, Sokolov K. Nanoparticles for targeted therapeutics and diagnostics. In:Handbook of Biomedical Optics . Boas DA, Pitris CP, Ramanujam N (Eds). Taylor & Francis, London, UK, 697-721 (2011). nn Provides a detailed overview of nanoparticle-based agents with diagnostic and therapeutic value.
79. Aaron J, Nitin N, Travis K et al. Imaging of epidermal growth factor receptor in early carcinogenesis using plasmon resonance coupling of metal nanoparticles. J. Biomed. Opt. 12(3), 034007 (2007).
80. El-Sayed IH, Huang X, El-Sayed MA. Surface plasmon resonance scattering and absorption of anti-EGFR antibody conjugated gold nanoparticles in cancer diagnostics: Applications in oral cancer. Nano Letters 5(5), 829-834 (2005).
81. Skala MC, Crow MJ, Wax A, Izatt JA. Photothermal optical coherence tomography of epidermal growth factor receptor in live cells using immunotargeted gold nanospheres. Nano Letters 8(10), 3461-3467 (2008).
82. Yang XM, Skrabalak SE, Li ZY, Xia YN, Wang LHV. Photoacoustic tomography of a rat cerebral cortex in vivo with au nanocages as an optical contrast agent. Nano Letters 7(12), 3798-3802 (2007).
83. Mallidi S, Larson T, Aaron J, Sokolov K, Emelianov S. Molecular specific optoacoustic imaging with plasmonic nanoparticles. Optics Express 15(11), 6583-6588 (2007).
84. Aaron J, Nitin N, Travis K et al. Plasmon resonance coupling of metal nanoparticles for molecular imaging of carcinogenesis in vivo. J. Biomed. Opt. 12(3), 034007 (2007).
85. Aaron J, Travis K, Harrison N, Sokolov K. Dynamic imaging of molecular assemblies in live cells based on nanoparticle plasmon resonance coupling. Nano Letters 9(10), 3612-3618 (2009). n Details the use of gold nanoparticles for dynamic imaging of EGF receptor trafficking in live cells.
86. Ma LL, Feldman MD, Tam JM et al. Small Multifunctional nanoclusters (nanoroses) for targeted cellular imaging and therapy. ACS Nano 3(9), 2686-2696 (2009).
87. Skrabalak SE, Chen JY, Sun YG et al. Gold nanocages: synthesis, properties, and applications. Acc. Chem. Res. 41(12), 1587-1595 (2008).
88. Durr NJ, Larson T, Smith DK, Korgel BA, Sokolov K, Ben-Yakar A. Two-photon luminescence imaging of cancer cells using molecularly targeted gold nanorods. Nano Letters 7(4), 941-945 (2007).
89. Abrams MJ, Murrer BA. Metal compounds in therapy and diagnosis. Science 261(5122), 725-730 (1993).
90. Smith RW, Leppard B, Barnett NL, Millward-Sadler GH, Mccrae F, Cawley MI. Chrysiasis revisited: A clinical and pathological study. Br. J. Dermatol. 133(5), 671-678 (1995).
91. Beckett VL, Doyle JA, Hadley GA, Spear KL. Chrysiasis resulting from gold therapy in rheumatoid arthritis: Identification of gold by x-ray microanalysis. Mayo Clin. Pro. 57(12), 773-777 (1982).
92. Yun Patricia L, Arndt Kenneth A, Anderson RR. Q-switched laser-induced chrysiasis treated with long-pulsed laser. Arch. Dermatol. 138(8), 1012-1014 (2002).
93. Mahmoudi M, Azadmanesh K, Shokrgozar MA, Journeay WS, Laurent S. Effect of nanoparticles on the cell life cycle. Chem. Rev. 111(5), 3407-3432 (2011).
94. Javier DJ, Nitin N, Roblyer DM, Richards-Kortum R. Metal-based nanorods as molecule-specific contrast agents for reflectance imaging in 3D tissues. J. Nanophotonics 2(1), 23506 (2008).
95. Loo C, Hirsch L, Lee MH et al. Gold nanoshell bioconjugates for molecular imaging in living cells. Optics Letters 30(9), 1012-1014 (2005).
96. Bickford LR, Agollah G, Drezek R, Yu TK. Silica-gold nanoshells as potential intraoperative molecular probes for HER2-overexpression in ex vivo breast tissue using near-infrared reflectance confocal microscopy. Breast Cancer Res. Treat. 120(3), 547-555 (2010).
97. Day ES, Bickford LR, Slater JH, Riggall NS, Drezek RA, West JL. Antibody-conjugated gold-gold sulfide nanoparticles as multifunctional agents for imaging and therapy of breast cancer. Int. J. Nanomed. 5, 445-454 (2010).
98. Derfus AM, Chan WCW, Bhatia SN. Probing the cytotoxicity of semiconductor quantum dots. Nano Letters 4(1), 11-18 (2004).
99. Kumar R, Nyk M, Ohulchanskyy TY, Flask CA, Prasad PN. Combined optical and MR bioimaging using rare earth ion doped NaYF4 nanocrystals. Adv. Funct. Mater. 19(6), 853-859 (2009).
100. Setua S, Menon D, Asok A, Nair S, Koyakutty M. Folate receptor targeted, rare-earth oxide nanocrystals for bi-modal fluorescence and magnetic imaging of cancer cells. Biomaterials 31(4), 714-729 (2010).
101. So MK, Xu CJ, Loening AM, Gambhir SS, Rao JH. Self-illuminating quantum dot conjugates for in vivo imaging. Nat. Biotechnol. 24(3), 339-343 (2006).
102. Ji XJ, Shao RP, Elliott AM et al. Bifunctional gold nanoshells with a superparamagnetic iron oxide-silica core suitable for both MR imaging and photothermal therapy. J. Phys. Chem. C 111(17), 6245-6251 (2007).
103. Larson TA, Bankson J, Aaron J, Sokolov K. Hybrid plasmonic magnetic nanoparticles as molecular specific agents for MRI/optical imaging and photothermal therapy of cancer cells. Nanotechnology 18, 325101 (2007).
104. Mahmoudi M, Serpooshan V, Laurent S. Engineered nanoparticles for biomolecular imaging. Nanoscale 3(8), 3007-3026 (2011).
105. Tasciotti E, Liu XW, Bhavane R et al. Mesoporous silicon particles as a multistage delivery system for imaging and therapeutic applications. Nat. Nanotechnol. 3(3), 151-157 (2008).
106. Olson ES, Jiang T, Aguilera TA et al. Activatable cell penetrating peptides linked to nanoparticles as dual probes for in vivo fluorescence and MR imaging of proteases. Proc. Natl Acad. Sci. USA 107(9), 4311-4316 (2010).
107. Mahmoudi M, Hosseinkhani H, Hosseinkhani M et al. Magnetic resonance imaging tracking of stem cells in vivo using iron oxide nanoparticles as a tool for the advancement of clinical regenerative medicine. Chem. Rev. 111(2), 253-280 (2011).
108. Jin Y, Jia C, Huang S-W, O'Donnell M, Gao X. Multifunctional nanoparticles as coupled contrast agents. Nat. Commun. 1, 41 (2010).
109. Sampath L, Kwon S, Hall MA, Price RE, Sevick-Muraca EM. Detection of cancer metastases with a dual-labeled near-infrared/positron emission tomography imaging agent. Transl. Oncol. 3(5), U307-U371 (2010).
110. Ghosn B, Van De Ven AL, Tam J et al. Efficient mucosal delivery of optical contrast agents using imidazole-modified chitosan. J. Biomed. Opt. 15(1), 015003 (2010).
111. Van De Ven AL, Adler-Storthz K, Richards-Kortum R. Delivery of optical contrast agents using Triton-X100, part 1: Reversible permeabilization of live cells for intracellular labeling. J. Biomed. Opt. 14(2), 021012 (2009).
112. Van De Ven AL, Adler-Storthz K, Richards-Kortum R. Delivery of optical contrast agents using Triton-X100, part 2: Enhanced mucosal permeation for the detection of cancer biomarkers. J. Biomed. Opt. 14(2), 021013 (2009).
113. Grainger SJ, Serna JV, Sunny S, Zhou Y, Deng CX, El-Sayed MEH. Pulsed ultrasound enhances nanoparticle penetration into breast cancer spheroids. Mol. Pharm. 7(6), 2006-2019 (2010).
114. Kang B, Mackey MA, El-Sayed MA. Nuclear targeting of gold nanoparticles in cancer cells induces DNA damage, causing cytokinesis arrest and apoptosis. J. Am. Chem. Soc. 132(5), 1517-1519 (2010).
115. Oyelere AK, Chen PC, Huang XH, El-Sayed IH, El-Sayed MA. Peptide-conjugated gold nanorods for nuclear targeting. Bioconj. Chem. 18, 1490-1497 (2007).
116. Longmire M, Choyke PL, Kobayashi H. Clearance properties of nano-sized particles and molecules as imaging agents: Considerations and caveats. Nanomedicine 3(5), 703-717 (2008).